Novel Drug Regenerates Erectile Nerves Damaged by Prostate Surgery
News provided by
Share this article
Share this article
BRONX, N.Y., April 19, 2021 /PRNewswire/ Researchers at Albert Einstein College of Medicine have developed a topical drug that regenerates and restores the function of erectile nerves damaged by radical prostatectomy, the most common treatment for localized prostate cancer. The drug was tested in rats, and the findings were published online today in
JCI Insight.
These images show neurons cultured in petri dishes and treated with either control (inactive) siRNA (left) or the siRNA drug itself (FL2 siRNA) (right). Neurons treated with the drug regenerate their axons (the thin fibers extending from the neurons central bodies) at a significantly faster rate than control-treated neurons. Scale bar = 0.10 mm.
US FDA Approved Jemincare to Initiate Clinical Trial of Neutralizing Antibody JMB2002
USA - English
Share this article
Share this article
SHANGHAI, April 2, 2021 /PRNewswire/ On March 31, 2021, Jemincare group announced that their anti-SARS-CoV-2 neutralizing antibody, JMB2002, independently developed by Jemincare Shanghai Research Center, was approved by FDA for clinical trial in the United States.
Preclinical data showed that JMB2002 can precisely occupy the key epitope of the receptor binding domain (RBD) on the S1 subunit of the SARS-CoV-2 with human angiotensin-converting enzyme II (hACE2) binding interface, and has strong binding and blocking activities to the spike glycoproteins of mutant viruses including the South African mutant (B.1.351), the UK mutant (B.1.1.7) and the Brazilian mutant (P.1) .
Yingli Pharma announce promising topline results of a Phase II registration study for treatment of relapsed/refractory follicular lymphoma with the once daily oral PI3Kδ inhibitor, linperlisib
News provided by
Share this article
Share this article
Linperlisib provides significant clinical improvement in the treatment for patients with relapsed and/or refractory follicular lymphoma
Linperlisib has a differentiated and well manageable safety profile
SHANGHAI, March 31, 2021 /PRNewswire/ Shanghai Yingli Pharmaceutical Co., Ltd. (Yingli Pharma) announced topline results of a Phase II registration study of linperlisib, a PI3Kδ inhibitor, for the treatment of relapsed/refractory follicular lymphoma (FL). Linperlisib is a potent and highly selective oral PI3Kδ inhibitor that was developed for potentially more efficacious with a potentially more manageable and differentiated safety profile from other PI3Kδ class agents. The topline results of this single-arm Phase II stud
International Experts Provide Consensus on How to Administer Testosterone to Postmenopausal Women
News provided by
Share this article
Share this article
BURNSVILLE, Minn., April 1, 2021 /PRNewswire/ Today, the International Society for the Study of Women s Sexual Health (ISSWSH) published an in-depth, detailed evidence-based, peer-reviewed international guideline on how healthcare professionals should administer testosterone to postmenopausal women. Although women naturally produce significant quantities of testosterone from puberty on, by the time they reach menopause, about 50% of their body s testosterone has been lost. Such deficiency leads to reduced muscle mass and strength, increased body fat, and not infrequently to the sexual dysfunction commonly referred to as lost libido. For years, men have had many FDA-approved testosterone therapies, including less expensive generics. Women still have no FDA approved options. Against this void of FDA-approved options for women, h
Share this article
NORTH CHICAGO, Ill., April 1, 2021 /PRNewswire/ AbbVie (NYSE: ABBV) today announced that the
New England Journal of Medicine has published 24-week results from the Phase 3 SELECT-PsA 1 trial evaluating RINVOQ
™ (upadacitinib, 15 mg and 30 mg) in adults with active psoriatic arthritis who had responded inadequately or were intolerant to one or more non-biologic disease modifying anti-rheumatic drugs (DMARDs).
1 These data build on previously announced Phase 3 topline results showing that upadacitinib 15 mg and 30 mg met the primary endpoint of ACR20 response at week 12 versus placebo as well as key secondary endpoints.
1 These data show upadacitinib s potential to improve clinical and radiographic outcomes for people with psoriatic arthritis, a complex and progressive autoimmune disease, said Thomas Hudson, MD, senior vice president, research and development, chief scientific officer, AbbVie. Ultimately, our goal is to help more patients achieve d